Document Detail


Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
MedLine Citation:
PMID:  17274978     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Activin receptor-like kinase 5 (ALK5) is a type I receptor of transforming growth factor (TGF)-beta. ALK5 inhibition has been reported to attenuate the tissue fibrosis including pulmonary fibrosis, renal fibrosis and liver fibrosis. To elucidate the inhibitory mechanism of ALK5 inhibitor on pulmonary fibrosis in vivo, we performed the histopathological assessment, gene expression analysis of extracellular matrix (ECM) genes and immunohistochemistry including receptor-activated Smads (R-Smads; Smad2/3), CTGF, myofibroblast marker (alpha-smooth muscle actin; aSMA) and type I collagen deposition in the lung using Bleomycin (BLM)-induced pulmonary fibrosis model. ALK5 inhibitor, SB-525334 (10 mg/kg or 30 mg/kg) was orally administered at twice a day. Lungs were isolated 5, 7, 9 and 14 days after BLM treatment. BLM treatment led to significant pulmonary fibrotic changes accompanied by significant upregulation of ECM mRNA expressions, Smad2/3 nuclear translocation, CTGF expression, myofibroblast proliferation and type I collagen deposition. SB-525334 treatment attenuated the histopathological alterations in the lung, and significantly decreased the type I and III procollagen and fibronectin mRNA expression. Immunohistochemistry revealed that SB-525334 treatment showed significant attenuation in Smad2/3 nuclear translocation, decrease in CTGF-expressing cells, myofibroblast proliferation and type I collagen deposition. These results suggest that ALK5 inhibition attenuates R-Smads activation thereby attenuates pulmonary fibrosis.
Authors:
Hiroyuki Higashiyama; Daisuke Yoshimoto; Toshihiko Kaise; Shigeki Matsubara; Masatoshi Fujiwara; Hideo Kikkawa; Satoshi Asano; Mine Kinoshita
Related Documents :
19996158 - Effect of pregnancy and progesterone concentration on expression of genes encoding for ...
19422658 - Tenascins and their implications in diseases and tissue mechanics.
12710748 - Effect of transforming growth factor-beta1, interleukin-6, and interferon-gamma on the ...
17173248 - Glomerular expression of ctgf, tgf-beta 1 and type iv collagen in diabetic nephropathy.
17467788 - Expression of activin pathway genes in granulosa cells of dominant and subordinate bovi...
17102128 - Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival res...
Publication Detail:
Type:  Journal Article     Date:  2006-12-24
Journal Detail:
Title:  Experimental and molecular pathology     Volume:  83     ISSN:  0014-4800     ISO Abbreviation:  Exp. Mol. Pathol.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-06-05     Completed Date:  2007-08-06     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0370711     Medline TA:  Exp Mol Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  39-46     Citation Subset:  IM    
Affiliation:
Pharmacology Department, Tsukuba Research Laboratories, GlaxoSmithKline KK, 43 Wadai, Tsukuba, Ibaraki, 300-4247, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Active Transport, Cell Nucleus
Activin Receptors, Type I / antagonists & inhibitors*,  metabolism*
Animals
Bleomycin / pharmacology*
Cell Proliferation
Collagen Type I / metabolism
Connective Tissue Growth Factor
Extracellular Matrix Proteins / genetics
Gene Expression Regulation / drug effects
Immediate-Early Proteins / metabolism
Immunohistochemistry
Intercellular Signaling Peptides and Proteins / metabolism
Male
Mice
Mice, Inbred BALB C
Protein Kinase Inhibitors / pharmacology*
Protein-Serine-Threonine Kinases
Pulmonary Fibrosis / chemically induced,  enzymology*,  pathology*
RNA, Messenger / genetics
Receptors, Transforming Growth Factor beta / antagonists & inhibitors*,  metabolism*
Smad2 Protein / metabolism
Smad3 Protein / metabolism
Chemical
Reg. No./Substance:
0/Collagen Type I; 0/Ctgf protein, mouse; 0/Extracellular Matrix Proteins; 0/Immediate-Early Proteins; 0/Intercellular Signaling Peptides and Proteins; 0/Protein Kinase Inhibitors; 0/RNA, Messenger; 0/Receptors, Transforming Growth Factor beta; 0/Smad2 Protein; 0/Smad2 protein, mouse; 0/Smad3 Protein; 0/Smad3 protein, mouse; 11056-06-7/Bleomycin; 139568-91-5/Connective Tissue Growth Factor; EC 2.7.1.11/TGF-beta type I receptor; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.30/Activin Receptors, Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diffusion analysis of glucocorticoid receptor and antagonist effect in living cell nucleus.
Next Document:  Regulation of clusterin expression in mammary epithelial cells.